Skip to main content
. 2020 Sep 14;12(9):2625. doi: 10.3390/cancers12092625

Figure 1.

Figure 1

Flow diagram of the screening study. All subjects had plasma apoA2-ATQ/AT levels determined. The apoA2-ATQ/AT cut-off for a positive value was ≤35 μg/mL. CECT, contrast-enhanced computed tomography; MRCP, magnetic resonance cholangiopancreatography; EUS, endoscopic ultrasonography; PC, pancreatic cancer; PCL, pancreatic cystic lesions; IPMN, intraductal papillary mucinous neoplasms; CP, chronic pancreatitis; NET, pancreatic neuroendocrine tumors; AIP, autoimmune pancreatitis.